Please ensure Javascript is enabled for purposes of website accessibility

Why Vaxart Shares Are Vaulting Higher Again

By Keith Speights – Jun 29, 2020 at 12:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Momentum from last week's big news continues.

What happened

Shares of Vaxart (VXRT 2.35%) were vaulting 10.8% higher as of 11:38 a.m. EDT on Monday after rising as much as 22.9% earlier in the day. The gain appears to be continued momentum from last Friday, when Vaxart's COVID-19 vaccine was selected to participate in the U.S. government's Operation Warp Speed initiative to rapidly develop a safe and effective novel coronavirus vaccine.

So what

Investors have been eager to buy shares of any company that receives positive publicity about its COVID-19 program. Vaxart's inclusion in Operation Warp Speed was exactly the kind of publicity the small biotech needed.

Scientist looking through a microscope

Image source: Getty Images.

The federal program had previously picked several COVID-19 vaccine candidates to fund for testing. Vaxart's is the first oral COVID-19 vaccine to be selected. The company's vaccine is being included in a preclinical trial with nonhuman primates.

What's especially impressive is that Vaxart chose its lead COVID-19 vaccine candidate only a little over a month ago. The company announced on May 20 that it had selected a COVID-19 vaccine candidate to advance and had contracted with KindredBio and Emergent BioSolutions to manufacture the vaccine. 

Now what

The biotech stock has potential catalysts on the way that just might keep its momentum going. Vaxart expects to announce results from its collaboration with Johnson & Johnson on a universal influenza vaccine soon. It also hopes to begin a phase 1 clinical study of its oral COVID-19 vaccine in the second half of 2020. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
$2.18 (2.35%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.